• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·002462.SZ
Share

Cachet Pharmaceutical Co., Ltd. Stocks

CN¥ 12.27Last Updated 12.10.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 539.64M

CN¥ 12.27
Key Takeaways

Risk factor

Modest price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in Beijing, China, in 1998, Cachet Pharmaceutical Co., Ltd. is a prominent Chinese enterprise engaged in the comprehensive wholesale and retail trade of pharmaceutical goods. The company's operations are multifaceted, encompassing the provision of medicines to hospitals, the large-scale distribution of biological products, medical devices, and traditional Chinese remedies. Additionally, it handles pharmaceutical logistics and actively manufactures its own line of medications. In Beijing, Cachet Pharmaceutical maintains a significant retail footprint with 150 chain stores, where customers can find a wide array of products, including pharmaceuticals, health supplements, medical instruments, cosmetics, daily essentials, and traditional Chinese medicines.

Company Valuation

Undervalued
6/7

Considering past and projected metrics, the stock is 'cheaper' than its peers. Specifically, the stock is fairly valued on P/E, undervalued on EV/EBITDA, underpriced on P

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

12.10.2026 13:09

The Saudis announced that they had intercepted new missiles. Riyadh promises stable oil supplies

12.10.2026 12:54

After Anthropic backed out of the deal, Amazon began considering a $7 billion acquisition of an AI startup

12.10.2026 12:04

Burry adjusted his bets on a market decline. Which stocks did he buy and sell?

12.10.2026 11:06

Oil prices fell after Trump's remarks about an "energy truce" between Russia and Ukraine

12.10.2026 10:45

The Hong Kong market is under pressure. Which stocks did the investor from “Shorting the Market” buy?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026